Celon Pharma
CLN.WACLN.WA · Stock Price
Historical price data
Overview
Celon Pharma's mission is to develop and provide innovative therapies for diseases with significant unmet medical needs, primarily in oncology and CNS, while maintaining financial stability through its generic drug operations. Its key achievement is building a fully integrated, GMP/GLP-compliant biopharma platform in Poland, supporting a pipeline of 11 proprietary drug candidates. The company's strategy is defined by this self-funded, end-to-end model, which reduces external dependencies and aims to capture full value from its R&D successes. This approach has established Celon as a unique and strategically important player in the European biopharmaceutical landscape.
Technology Platform
An integrated, in-house platform for small-molecule drug development encompassing proprietary discovery, medicinal chemistry, preclinical research, clinical development, and commercial-scale GMP manufacturing.
Pipeline
11| Drug | Indication | Stage | Watch |
|---|---|---|---|
| CPL500036 - low dose + CPL500036 - high dose + Placebo | Schizophrenia | Phase 2 | |
| Esketamine DPI - low dose + Esketamine DPI - medium dose + E... | Bipolar Depression | Phase 2 | |
| CPL207280 + Placebo | Type 2 Diabetes | Phase 2 | |
| Esketamine DPI - low dose + Esketamine DPI - medium dose + E... | Major Depressive Disorder | Phase 2 | |
| CPL500036 - low dose + CPL500036 - high dose + Placebo | Parkinson Disease | Phase 2 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competes in generics on cost and efficiency against global and regional players. In innovation, faces large biopharma and biotechs; differentiation comes from novel chemistry and capital-efficient integrated development. The hybrid model itself is a unique competitive positioning.